MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides

Area of Science:

• Molecular Biology
• Genetics
• Cancer Research

Background:

• Alternative splicing is a key mechanism for increasing protein diversity from a single gene.
• The MDM2 oncogene is known to produce numerous splice variants, exceeding 40 identified isoforms.
• Alterations in MDM2 mRNA expression and splicing are implicated in various cancers.

Purpose of the Study:

• To review the current understanding of MDM2 alternative splicing.
• To explore the functional significance of different MDM2 isoforms.
• To discuss the therapeutic potential of targeting MDM2 with antisense oligonucleotides.

Main Methods:

• Literature review of studies on MDM2 gene expression and alternative splicing.
• Analysis of identified MDM2 splice variants and their associated functions.
• Review of preclinical and clinical research on MDM2-targeted antisense oligonucleotide therapy.

Main Results:

• Over 40 distinct MDM2 splice variants have been identified in both tumor and normal tissues.
• Different MDM2 isoforms may possess varying functions, contributing to oncogenesis or tumor suppression.
• Antisense oligonucleotides targeting MDM2 show promise as a potential cancer therapeutic strategy.

Conclusions:

• Alternative splicing of MDM2 significantly contributes to protein diversity and cellular function.
• Understanding MDM2 splice variants is crucial for comprehending their role in cancer.
• Targeting MDM2 with antisense oligonucleotides represents a developing approach for cancer therapy.